Scientists track radioactive drug through 8 healthy men
NCT ID NCT07314320
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial studied how a single dose of the experimental drug OPC-167832 is eliminated from the body. Eight healthy men took the drug, which was tagged with a tiny amount of radioactivity, and researchers measured how much came out in urine and stool. The goal was purely to understand the drug's journey, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OPC-167832 (a radioactive-labeled drug)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion, Inc
Lincoln, Nebraska, 68502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults